- Home
- SANA vs ELVN Comparison
SANA vs ELVN Comparison
Compare SANA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- ELVN
- Stock Information
- Founded
- SANA 2018
- ELVN 2016
- Country
- SANA United States
- ELVN United States
- Employees
- SANA N/A
- ELVN N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SANA Health Care
- ELVN Health Care
- Exchange
- SANA Nasdaq
- ELVN Nasdaq
- Market Cap
- SANA 983.4M
- ELVN 1.2B
- IPO Year
- SANA 2021
- ELVN 2020
- Fundamental
- Price
- SANA $4.90
- ELVN $23.97
- Analyst Decision
- SANA Strong Buy
- ELVN Strong Buy
- Analyst Count
- SANA 6
- ELVN 5
- Target Price
- SANA $8.00
- ELVN $41.20
- AVG Volume (30 Days)
- SANA 6.7M
- ELVN 433.1K
- Earning Date
- SANA 11-11-2025
- ELVN 11-07-2025
- Dividend Yield
- SANA N/A
- ELVN N/A
- EPS Growth
- SANA N/A
- ELVN N/A
- EPS
- SANA N/A
- ELVN N/A
- Revenue
- SANA N/A
- ELVN N/A
- Revenue This Year
- SANA N/A
- ELVN N/A
- Revenue Next Year
- SANA N/A
- ELVN $20.05
- P/E Ratio
- SANA N/A
- ELVN N/A
- Revenue Growth
- SANA N/A
- ELVN N/A
- 52 Week Low
- SANA $1.26
- ELVN $13.30
- 52 Week High
- SANA $7.30
- ELVN $29.79
- Technical
- Relative Strength Index (RSI)
- SANA 59.91
- ELVN 62.60
- Support Level
- SANA $5.12
- ELVN $20.10
- Resistance Level
- SANA $5.90
- ELVN $22.88
- Average True Range (ATR)
- SANA 0.56
- ELVN 0.96
- MACD
- SANA -0.02
- ELVN 0.13
- Stochastic Oscillator
- SANA 49.89
- ELVN 92.43
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.